Correction: Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE (Neurology (2017) 88 (1906-1911) DOI: 10.1212/WNL.0000000000003941);Risks and benefits of clopidogrel-aspirin in minor stroke or TIA

Neurology

Volumn 88, Issue 20, 2017, Pages 1906-1911

  Pan, Yuesong ^a,b   Jing, Jing ^a,b   Chen, Weiqi ^a,b   Meng, Xia ^a,b   Li, Hao ^a,b   Zhao, Xingquan ^a,b   Liu, Liping ^a,b   Wang, David ^c   Johnston, S Claiborne ^d   Wang, Yilong ^a,b   Wang, Yongjun ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DUAL ANTIPLATELET THERAPY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN BRUISING; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN ISCHEMIA; CHINA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MULTICENTER STUDY; RISK; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ASPIRIN; BRAIN ISCHEMIA; CHINA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85019899836     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000007482     Document Type: Erratum

References (15)

1. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11-19
2. Wang Y, Pan Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation 2015; 132: 40-46
3. The Cerebrovascular Disease Group of Chinese Medical Association. Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2014 [in Chinese]. Clin J Neurol 2015; 48: 258-273
4. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-2236
5. Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack: how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol 2016; 23: 1051-1057
6. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebocontrolled trial. Lancet 2004; 364: 331-337
7. Wang Y, Johnston SC; CHANCE Investigators. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010; 160: 380-386
8. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
9. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307
10. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010; 103: 1128-1135
11. Wang D, Gui L, Dong Y, et al. Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial. Stroke Vasc Neurol 2016; 1: 29-36
12. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969
13. Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 2015; 169: 899-905 e891
14. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 2006; 1: 158-159
15. Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study. Stroke 2014; 45: 663-669